Medical Industry Feature

ReachMD

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

  1. 6. Juli

    Socioeconomic Determinants and Outcomes in Proliferative Sickle Retinopathy

    Host: Maria Berrocal Guest: Audina Berrocal, MD Does socioeconomic status influence outcomes in proliferative sickle retinopathy? In this episode of Clinical Minute: Retina, host Maria Berrocal, MD, speaks with Audina "Nina" Berrocal, MD, of Bascom Palmer Eye Institute, who published a retrospective review of more than 100 patients with proliferative sickle retinopathy. They explore whether the integrated care model at Bascom Palmer may account for results that don't translate to other parts of the country. The conversation also touches on newborn screening programs in Florida and the importance of sickle cell centers in high-incidence communities.

    5 Min.

  2. 17. Juni

    Redefining Durability in Wet AMD: Insights from the SOL‑1 Superiority Trial

    Host: Priya Vakharia, MD Guest: Andrew Moshfeghi, MD The SOL-1 Phase 3 superiority trial compared the efficacy and safety of the investigational product OTX-TKI (axitinib intravitreal hydrogel) with aflibercept 2 mg. The primary endpoint was proportion of subjects who maintained visual acuity, defined as 15 Early Treatment Diabetic Retinopathy Study letters of best-corrected visual acuity loss from baseline at Week 36. Based on the findings, SOL-1 met its primary endpoint and demonstrated a statistically significant high proportion of subjects maintained visual acuity with OTX-TKI vs. aflibercept 2 mg at Week 36. OTX-TKI demonstrated stability in vision and anatomic outcomes through 36 weeks, with evidence of extended durability and delayed need for rescue therapy. This could contribute to the goal of maintaining disease control in wet AMD. OTX-TKI was generally well tolerated through Week 52. Ocular adverse events were reported in 52.9% of OTX-TKI-treated subjects vs. 33.7% of aflibercept-treated subjects. There were no treatment-related serious adverse events (SAEs) and no cases of retinal vasculitis. The most common AEs reported in OTX-TKI subjects were vitreous floaters (12.4%), cataract (7.1%) and conjunctival hemorrhage (6.5%). To learn more about the SOL-1 trial design, findings, and implications for care, tune in to hear Dr. Priya Vakharia speak with Dr. Andrew Moshfeghi. Reference: Heier …

    11 Min.

  3. 19. Mai

    Expandable Cages Enhance Minimally Invasive Spinal Fusion

    Guest: Ibrahim Hussain, M.D. Neurological spine surgeon Dr. Ibrahim Hussain explains how expandable cages are being used in minimally invasive transforaminal lumbar interbody fusions to optimize patient outcomes. These cages can be inserted with a very low profile to restore height and lordosis, and enable a faster recovery. At Och Spine at NewYork-Presbyterian, surgeons are pursuing innovative solutions to provide a better quality of life for patients with degenerative disc disease and other spine conditions. © 2026 NewYork-Presbyterian

    2 Min.

  4. 15. Mai

    ReDiscover-2: Currently Enrolling Patients With PIK3CA-Mutated Advanced Breast Cancer

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDiscover trial of zovegalisib + fulvestrant that supported initiation of the Phase 3 ReDiscover-2 study3,4, which is currently enrolling. They also discuss ReDiscover-2 eligibility criteria, along with patient selection and screening considerations, using hypothetical case scenarios. Dr. Sammons is the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts. References: Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7)doi:10.3390/ijms22073464 Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery. 2024;14(2):240–257. doi:10.1158/2159-8290.cd-23-0944 ClinicalTrials.gov. NCT06982521. Accessed April 12, 2026. https://clinicaltrials.gov/study/NCT06982521 Rugo HS, Saura C, Jhaveri K, et al. Poster PS5-08-25: …

    17 Min.

  5. 13. Mai

    Improving Preterm Birth Outcomes with Virtual Cervix Technology

    Guest: Mirella Mourad, M.D. On this episode of Advances in Care, host Erin Welsh is joined by Dr. Mirella Mourad, maternal-fetal medicine specialist at NewYork-Presbyterian and co-director of the Preterm Birth Prevention Center at Columbia, to explore a groundbreaking new technology aimed at improving the diagnosis and treatment of preterm birth. Preterm birth impacts approximately 1 in 10 pregnancies in the United States, making it a leading cause of neonatal complications and long-term health challenges. But despite its prevalence and associated risks, innovative solutions to address the condition have lagged behind. To address this gap, Dr. Mourad and her collaborator, Dr. Kristin Meyers, a professor of mechanical engineering at Columbia’s School of Engineering, are developing a new tool: a patient-specific “digital twin” of the cervix. This advanced technology has the potential to revolutionize obstetric care for patients by allowing clinicians to test new treatment methods, collect data to better understand why certain people are at risk for preterm birth, and overall, catalyze innovation in the historically under-researched field of maternal-fetal medicine, ultimately helping to drive better outcomes and successful pregnancies. Dr. Mourad also discusses how this digital twin can potentially assist with identifying women with placenta accreta spectrum disorder and inform more precise and …

    21 Min.

  6. 7. Mai

    Engaging Patients and Caregivers About Digital Therapeutics

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maggie Emerson, DNP, APRN, PMHNP-BC Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That’s why Dr. Charles Turck speaks with Dr. Maggie Emerson about how we can best partner with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha.

    12 Min.

  7. 20. Apr.

    From Monoamines to Neurocircuits: Our Evolving Understanding of Depression

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joseph Goldberg, MD Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity, chemical imbalance, and negative cognitive biases. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.

    12 Min.

  8. 1. Apr.

    Neuroplasticity: A Potential Target for the Treatment of Depression

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Madhukar H. Trivedi, MD The brain is constantly changing as a result of experience, stress, emotional processing, learning, and memory.1 And neuroplasticity adds another layer to these approaches by focusing on what’s actually changing in the brain.2 Tune in with Dr. Charles Turck as he speaks with Dr. Madhukar Trivedi, Founding Director of the Center for Depression Research and Clinical Care and Chief of the Division of Mood Disorders at the University of Texas Southwestern Medical Center in Dallas, Texas. References: Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77. Mateos-Aparicio P, Rodriguez-Moreno A. The impact of studying brain plasticity. Front Cell Neurosci. 2019;13:66.

    15 Min.
Alle anzeigen (36)

Info

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Informationen

  • Erstellt von
    ReachMD
  • Jahre aktiv
    2014 - 2026
  • Folgen
    36
  • Bewertung
    Unbedenklich
  • Copyright
    © Copyright 2026 ReachMD. All rights reserved.
  • Sendungswebsite
    Medical Industry Feature

Mehr von ReachMD